Table 6.
Results of first and two consecutive detections of galactomannan in serum of critically ill CORD patients
| Single GM detection (95% CI) | Two consecutive GM detections (95% CI) (n = 48) | |||
|---|---|---|---|---|
| Positive for a first test (n = 55) | Positive for a second test (n = 48) | At least one positive of the two consecutive tests | Both positive for the two consecutive tests | |
| Sensitivity (%) | 46.2 (33.3-59.1) | 50.0 (35.9-54.1) | 53.8 (39.7-67.9) | 41.7 (27.8-55.6) |
| Specificity (%) | 83.3 (73.4-93.2) | 93.5 (86.5-100) | 81.0 (69.9-92.1) | 93.5 (86.5-100) |
| PPV (%) | 46.2 (33.3-59.1) | 75.0 (62.7-87.3) | 46.7 (32.6-60.8) | 71.4 (58.7-84.1) |
| NPV (%) | 83.3 (73.4-93.2) | 82.9 (72.2-93.6) | 85.0 (74.9-95.1) | 80.6 (69.7-91.5) |
| TCR (%) | 74.5 (63.0-86.0) | 81.4 (70.4-91.4) | 74.5 (62.2-86.8) | 79.1 (67.9-90.3) |
CORD, chronic obstructive respiratory disease; NPV, negative predictive value; PPV, positive predictive value; TCR, total consistent rate.